pd-1-in-22

PD-1-IN-22 is a potent inhibitor of the programmed cell death-1 (PD-1) programmed cell death-ligand 1 (PD-L1) interaction, with an IC50 of 92.3 nM.

PD-1 PD-L1-IN-22, a small molecule inhibitor (IC50: 0.732 μM), blocks PD-1 PD-L1 protein-protein interactions and can be utilized to study cancer, infectious diseases, and autoimmune diseases.

Envafolimab (ASC 22) is a humanized monoclonal antibody targeting programmed cell death ligand-1 (PD-L1), with antitumor activity. It blocks the interaction between PD-L1 and PD-1, and is used in studies of solid tumors.

CSF1R-IN-22 (Compound C19), a potent orally administered CSF-1R selective inhibitor (IC50 <6 nM), significantly enhances CXCL9 secretion from M2 macrophages and promotes CD8+ T cell infiltration. Moreover, it amplifies the anti-tumor immune responses in conjunction with anti-PD-1 and triggers apoptosis in tumor cells. Additionally, CSF1R-IN-22 effectively reprograms M2-like TAMs (tumor-associated macrophages) to an M1 phenotype, modulates the tumor microenvironment (TME) by fostering the recruitment of CD8+ T cells, and diminishes the presence of immunosuppressive Tregs and MDSCs [1].